Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
✍ Scribed by Johannes Brettschneider; Axel Petzold; Sigurd D. Süßmuth; Georg B. Landwehrmeyer; Albert C. Ludolph; Jan Kassubek; Hayrettin Tumani
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 77 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We aimed to evaluate the potential of the cerebrospinal fluid (CSF) axonal damage biomarker NfH^SMI35^ in the laboratory‐supported differential diagnosis of parkinsonian syndromes. Patients with idiopathic Parkinson's disease (PD; n = 22), multiple‐system atrophy (MSA; n = 21), progressive supranuclear palsy (PSP; n = 21), corticobasal degeneration (CBD; n = 6), and age‐matched controls (n = 45) were included. CSF levels of NfH^SMI35^ were measured using ELISA. Levels of CSF NfH^SMI35^ were elevated in PSP compared to PD and controls (P < 0.05 each). They were also significantly higher in MSA than in PD and controls (P < 0.05 each). NfH^SMI35^ differentiated PD from PSP with a sensitivity of 76.5% and a specificity of 94.4%. Axonal damage as measured by CSF NfH^SMI35^ is most prominent in the more rapidly progressive syndromes PSP and MSA as compared to PD or CBD. CSF NfH^SMI35^ may therefore be of some value for the laboratory‐supported differential diagnosis of atypical parkinsonian syndromes. © 2006 Movement Disorder Society